Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is often treated with ABL1 inhibitors.
• BCR-ABL1 compound mutations can confer resistance to these therapies.
• Targeting resistance mechanisms is crucial for effective CML treatment.

Observation:

• A patient with chronic myeloid leukemia (CML) exhibited resistance to ABL1 inhibitors.
• The patient's leukemia harbored BCR-ABL1 compound mutations.
• This clinical case provided an opportunity to test a novel combination therapy.

Findings:

• The combination of ponatinib (an ATP-site inhibitor) and asciminib (an allosteric inhibitor) was clinically validated.
• This dual-targeting approach effectively addressed the resistance mediated by BCR-ABL1 compound mutations.
• Successful treatment was observed in the CML patient.

Implications:

• This study provides clinical evidence supporting the combination of ponatinib and asciminib for CML.
• The findings offer a potential strategy to overcome ABL1 inhibitor resistance in CML.
• This approach may improve outcomes for CML patients with challenging mutations.